Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: TST014
MIFTS: 52

Testicular Cancer

Categories: Cancer diseases, Endocrine diseases, Reproductive diseases
Genes Variations Tissues Related diseases Publications Drugs
Sources

Aliases & Classifications for Testicular Cancer

About this section

MalaCards integrated aliases for Testicular Cancer:

Name: Testicular Cancer 12 36 54 6 42 15
Malignant Neoplasm of Testis 71 32
Testicular Carcinoma 54 17
Testicular Neoplasms 44 71
Testicular Malignant Germ Cell Tumor 71
Childhood Neoplasm of the Testis 12
Pediatric Testicular Neoplasm 12
Childhood Testicular Neoplasm 71
Carcinoma of the Testis 71
Testicular Neoplasm 17
Neoplasm of Testis 12
Testicular Tumors 15
Testicular Tumor 12
Testis Neoplasm 12
Testis Cancer 12

Classifications:

MalaCards categories:
Global: Cancer diseases
Anatomical: Endocrine diseases Reproductive diseases
See all MalaCards categories (disease lists)
ICD10: 32


External Ids:

Disease Ontology 12 DOID:2998
KEGG 36 H00023
ICD9CM 34 186
MeSH 44 D013736
SNOMED-CT 67 126900000 94087009
ICD10 32 C62 C62.9
UMLS 71 C0039590 C0153594 C0677483 more
Sources

Summaries for Testicular Cancer

About this section
MedlinePlus : 42 Testicles, or testes, make male hormones and sperm. They are two egg-shaped organs inside the scrotum, the loose sac of skin behind the penis. You can get cancer in one or both testicles. Testicular cancer mainly affects young men between the ages of 20 and 39. It is also more common in men who Have had abnormal testicle development Have had an undescended testicle Have a family history of the cancer Symptoms include pain, swelling, or lumps in your testicles or groin area. Doctors use a physical exam, lab tests, imaging tests, and a biopsy to diagnose testicular cancer. Most cases can be treated, especially if found early. Treatment options include surgery, radiation, and/or chemotherapy. Regular exams after treatment are important. Treatments may also cause infertility. If you may want children later on, you should consider sperm banking before treatment. NIH: National Cancer Institute

MalaCards based summary : Testicular Cancer, also known as malignant neoplasm of testis, is related to testicular leydig cell tumor and testicular seminoma. An important gene associated with Testicular Cancer is STK11 (Serine/Threonine Kinase 11). The drugs Docetaxel and Tyrosine have been mentioned in the context of this disorder. Affiliated tissues include testicles, testis and lymph node.

Disease Ontology : 12 A male reproductive system cancer that is located in the testicles.

KEGG : 36 Testicular germ cell tumor (TGCT) comprises about 98% of all testicular neoplasms and is thereby the most common malignancy among young males. Overall, three different entities of TGCT can be distinguished: teratomas and yolk sac tumors of newborns and infants, seminomatous and nonseminomatous germ cell tumors of adolescents and young adults, and spermatocytic seminoma of elderly men. Recent studies of TGCTs have suggested that overexpression of cyclin D2 is a very early, possibly the oncogenic, event in GC tumorigenesis.

Wikipedia : 74 Testicular cancer is cancer that develops in the testicles, a part of the male reproductive system.... more...

Sources

Related Diseases for Testicular Cancer

About this section

Diseases related to Testicular Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 538)
# Related Disease Score Top Affiliating Genes
1 testicular leydig cell tumor 32.5 INSL3 CGB3
2 testicular seminoma 32.5 CGB3 AFP
3 testicular disease 32.3 RXFP2 MIR199A1 INSL3 AFP
4 cryptorchidism, unilateral or bilateral 32.2 SHBG RXFP2 INSL3 CGB5 ALPP AFP
5 nonseminomatous germ cell tumor 32.0 CGB5 AFP
6 teratoma 32.0 CGB5 CGB3 AFP
7 seminoma 31.7 TDRG1 MAGEA4 FGFR3 CGB5 CGB3 ALPP
8 germ cell cancer 31.6 MIR199A1 ALPP AFP
9 testicular germ cell tumor 31.3 STK11 FGFR3 BCL10 AFP
10 choriocarcinoma 31.1 CGB5 CGB3 ALPP
11 endodermal sinus tumor 31.1 MIR199A1 CGB3 ALPP AFP
12 mixed germ cell tumor 31.0 CGB3 AFP
13 malignant teratoma 31.0 CGB5 AFP
14 extragonadal germ cell cancer 30.9 CGB5 AFP
15 testicular torsion 30.8 RXFP2 INSL3 CGB5
16 androgen insensitivity syndrome 30.7 SHBG RXFP2 INSL3
17 chromosomal triplication 30.6 CGB3 AFP
18 spermatocytoma 30.5 MAGEA4 FGFR3 AFP
19 gonadal germ cell tumor 30.5 CGB5 AFP
20 testicular spermatocytic seminoma 30.4 MAGEA4 FGFR3
21 tuberculous epididymitis 30.4 CGB3 AFP
22 germinoma 30.3 CGB5 CGB3 ALPP AFP
23 gonadal dysgenesis 30.3 SHBG CGB5 CGB3
24 adenomatoid tumor 30.2 CGB5 AFP
25 sertoli-leydig cell tumor 30.1 INSL3 ALPP AFP
26 gonadoblastoma 30.1 CGB5 CGB3 ALPP
27 dysgerminoma of ovary 30.0 ALPP AFP
28 dowling-degos disease 1 30.0 STK11 FGFR3
29 squamous cell carcinoma 29.9 STK11 MAGEA4 FGFR3 CTAG1B BOK-AS1
30 rete testis neoplasm 11.3
31 embryonal carcinoma 11.2
32 testicular germ cell cancer 11.1
33 testis sarcoma 11.1
34 carney complex variant 11.1
35 rete testis adenocarcinoma 11.0
36 testis refractory cancer 11.0
37 persistent mullerian duct syndrome 11.0
38 spermatocele 11.0
39 testicular brenner tumor 11.0
40 germ cells tumors 10.8
41 mature teratoma 10.6
42 in situ carcinoma 10.6
43 infertility 10.6
44 hypogonadism 10.6
45 anorchia 10.5 RXFP2 INSL3 CGB5
46 gestational trophoblastic neoplasm 10.5 CGB5 CGB3 AFP
47 trophoblastic neoplasm 10.5 CGB5 CGB3 AFP
48 corpus luteum cyst 10.5 CGB5 AFP
49 ectopic pregnancy 10.5 CGB5 CGB3 AFP
50 disorder of sexual development 10.5 SHBG RXFP2 INSL3

Graphical network of the top 20 diseases related to Testicular Cancer:



Diseases related to Testicular Cancer
Sources

Symptoms & Phenotypes for Testicular Cancer

About this section
Sources

Drugs & Therapeutics for Testicular Cancer

About this section

Drugs for Testicular Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 142)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Docetaxel Approved, Investigational Phase 4 114977-28-5 148124
2
Tyrosine Approved, Investigational, Nutraceutical Phase 4 60-18-4 6057
3
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
4
Testosterone Approved, Investigational Phase 2, Phase 3 58-22-0 6013
5
Etoposide Approved Phase 3 33419-42-0 36462
6
Bleomycin Approved, Investigational Phase 3 11056-06-7 5360373
7
Oxaliplatin Approved, Investigational Phase 3 61825-94-3 5310940 9887054 6857599 43805
8
Ifosfamide Approved Phase 3 3778-73-2 3690
9
Paclitaxel Approved, Vet_approved Phase 3 33069-62-4 36314
10
Vinblastine Approved Phase 3 865-21-4 13342 241903
11 Hormones Phase 2, Phase 3
12 Androgens Phase 2, Phase 3
13 Antirheumatic Agents Phase 3
14 Hormone Antagonists Phase 2, Phase 3
15 Calcium, Dietary Phase 3
16 Etoposide phosphate Phase 3
17 Antibiotics, Antitubercular Phase 3
18 Anti-Bacterial Agents Phase 3
19
Isophosphamide mustard Phase 3 100427
20 Alkylating Agents Phase 3
21 Albumin-Bound Paclitaxel Phase 3
22 Antimitotic Agents Phase 3
23 Tubulin Modulators Phase 3
24
Calcium Nutraceutical Phase 3 7440-70-2 271
25
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
26
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2 1177-87-3
27
Dexamethasone Approved, Investigational, Vet_approved Phase 2 50-02-2 5743
28
Furosemide Approved, Vet_approved Phase 1, Phase 2 54-31-9 3440
29
Magnesium Sulfate Approved, Investigational, Vet_approved Phase 1, Phase 2 7487-88-9 24083
30
Chlorpheniramine Approved Phase 1, Phase 2 113-92-8, 132-22-9 2725
31
Mannitol Approved, Investigational Phase 1, Phase 2 69-65-8 453 6251
32
Pancrelipase Approved, Investigational Phase 2 53608-75-6
33
Epirubicin Approved Phase 2 56420-45-2 41867
34
Everolimus Approved Phase 2 159351-69-6 6442177 70789204
35
Lorazepam Approved Phase 2 846-49-1 3958
36
Sunitinib Approved, Investigational Phase 2 341031-54-7, 557795-19-4 5329102
37
Vincristine Approved, Investigational Phase 2 2068-78-2, 57-22-7 5978
38
Temozolomide Approved, Investigational Phase 2 85622-93-1 5394
39
Palbociclib Approved, Investigational Phase 2 571190-30-2 11431660 5005498 5330286
40
Ondansetron Approved Phase 2 99614-02-5 4595
41
Levoleucovorin Approved, Investigational Phase 2 68538-85-2 149436
42
leucovorin Approved Phase 2 58-05-9 6006
43
Fluorouracil Approved Phase 2 51-21-8 3385
44
Carboplatin Approved Phase 2 41575-94-4 10339178 498142 38904
45
Cisplatin Approved Phase 2 15663-27-1 84093 441203 2767
46
Testosterone undecanoate Approved, Investigational Phase 2 5949-44-0
47
Testosterone enanthate Approved Phase 2 315-37-7 9416
48
Methyltestosterone Approved Phase 2 58-18-4 6010
49
Durvalumab Approved, Investigational Phase 2 1428935-60-7
50
Thiotepa Approved, Investigational Phase 2 52-24-4 5453

Interventional clinical trials:

(show top 50) (show all 120)
# Name Status NCT ID Phase Drugs
1 A Single Arm, Multi-center Study to Assess the Efficacy and Safety of Docetaxel Combined With Carboplatin Plus Anlotinib as First Line Treatment in Non-squamous Non-small-cell Lung Cancer (NSCLC) Unknown status NCT03799601 Phase 4 Anlotinib;Docetaxel;Carboplatin
2 Taste and Smell Changes in Testicular Cancer Patients Treated With Cisplatin Based Chemotherapy Completed NCT01641172 Phase 4
3 A Phase III Study Of Reduced Therapy In The Treatment Of Children With Low And Intermediate Risk Extracranial Germ Cell Tumors Unknown status NCT00053352 Phase 3 cisplatin;etoposide
4 A Randomized Double-blind Study of Testosterone Replacement Therapy or Placebo in Testicular Cancer Survivors With Mild Leydig Cell Insufficiency (Einstein-intervention) Completed NCT02991209 Phase 2, Phase 3 Testosterone;Placebos
5 A Randomized Double Blinded Trial of Topical Caphosol to Prevent Oral Mucositis in Children Undergoing Hematopoietic Stem Cell Transplantation Completed NCT01305200 Phase 3 supersaturated calcium phosphate rinse
6 RANDOMIZED MULTIINSTITUTIONAL PHASE III TRIAL OF BEP AND HIGH DOSE CHEMOTHERAPY VERSUS BEP ALONE IN PREVIOUSLY UNTREATED PATIENTS WITH POOR RISK GERM CELL TUMORS Completed NCT00002596 Phase 3 carboplatin;cisplatin;cyclophosphamide;etoposide
7 A Randomized Phase III Study Comparing One Course of Adjuvant Bleomycin, Etoposide and Cisplatin (BEP) and One Course of Carboplatin AUC7 in Clinical Stage I Seminomatous Testicular Cancer Recruiting NCT02341989 Phase 3 Bleomycin Etoposide and Cisplatin;Carboplatin
8 A Single Group Trial Evaluating One Cycle of Adjuvant BEP Chemotherapy in High Risk, Stage 1 Non-seminomatous Germ Cell Tumours of the Testis (NSGCTT) Active, not recruiting NCT01726374 Phase 3 BEP(500)
9 A Risk-Adapted Strategy of the Use of Dose-Dense Chemotherapy in Patients With Poor-Prognosis Disseminated Non-Seminomatous Germ Cell Tumors Active, not recruiting NCT00104676 Phase 3 cisplatin;etoposide;ifosfamide;oxaliplatin;paclitaxel
10 A Randomized Phase III Study of Paclitaxel, Ifosfamide and Cisplatin Versus Vinblastine, Ifosfamide and Cisplatin as Second-Line Therapy for Patients With Relapsed/Resistant Germ Cell Tumors Terminated NCT00072215 Phase 3 cisplatin;ifosfamide;paclitaxel;vinblastine
11 Sorafenib (NEXAVAR) Monotherapy in Patients With Inoperable/Recurrent Germ Cell Carcinoma Refractory to Chemotherapy Unknown status NCT00772694 Phase 2 sorafenib
12 A Prospective Phase II Trial of Cabazitaxel in Male Patients With Chemotherapy Pre-treated Metastatic Nonseminomatous Germ-cell Tumors Unknown status NCT02115165 Phase 2 Cabazitaxel
13 Tandem High-Dose Chemotherapy (HDCT) With Peripheral-Blood Stem-Cell Rescue for Patients With Metastatic Germ-Cell Tumors Failing First-Line Treatment Unknown status NCT01172912 Phase 2 carboplatin;cisplatin;dexamethasone;etoposide;ifosfamide
14 Phase I/II Multicentre Trial of Salvage Chemotherapy With Gem-TIP for Relapsed Germ Cell Cancer Unknown status NCT00551122 Phase 1, Phase 2 cisplatin;gemcitabine hydrochloride;ifosfamide;paclitaxel
15 A Prospective Multicenter Phase II Trial of Gemcitabine, Cisplatin, and Ifosfamide (GIP) in Patients With Relapsed Non-Seminomatous Germ-Cell Tumors (NSGCT) and a Predicted Favorable Prognosis Unknown status NCT00127049 Phase 2 gemcitabine, ifosfamide, cisplatin, G-CSF
16 A Phase II Clinical Study to Evaluate the Safety and Efficacy of FalateScan (Technetium Tc 99m EC20) in Patients With Known Suspected Recurrent or Metastatic Cancer From a Solid Tumor Completed NCT01684098 Phase 2 Tc 99m EC20
17 Randomized Phase 2 Study of Conventional Dose Chemotherapy Versus High Dose Sequential Chemotherapy as First-line Therapy for Metastatic Poor Prognosis Germ Cell Tumors Completed NCT02161692 Phase 2 Cyclophosphamide;Etoposide;Cisplatin;Bleomycin;Carboplatin
18 Sequential High-Dose Chemotherapy Combining Two Mobilization and Cyto-Reductive Treatments Followed by Three High-Dose Chemotherapy Regimens Supported by Autologous Stem Cell Transplantation Completed NCT00231582 Phase 2 epirubicin;paclitaxel;etoposide;ifosfamide;carboplatin
19 Phase II Study of Avelumab in Multiple Relapsed/Refractory Testicular Germ Cell Cancer. Completed NCT03403777 Phase 2 Avelumab
20 A Phase II Study of Gemcitabine, Oxaliplatin, and Paclitaxel in Patients With Refractory Germ Cell Carcinoma Completed NCT00183820 Phase 2 paclitaxel, gemcitabine, and oxaliplatin
21 A Single Arm, Open-label Multicenter Phase II Trial of Everolimus in Patients With Relapsed/Refractory Germ Cell Cancer Completed NCT01242631 Phase 2 Everolimus
22 High Dose Carboplatin, Etoposide, Cyclophosphamide and Autologous Bone Marrow Transplantation for Relapsed and Refractory Germ Cell Cancer: A Phase II Pilot Study Completed NCT00002943 Phase 2 carboplatin;cyclophosphamide;etoposide
23 Phase II Trial of Stereotactic Radiosurgery Boost Following Surgical Resection for Brain Metastases Completed NCT00587964 Phase 2
24 A Phase II Study of BMS-247550 In Advanced Germ Cell Tumor Patients - THERAPEUTIC/DIAGNOSTIC PROTOCOL Completed NCT00070096 Phase 2 ixabepilone
25 Phase II Study of Everolimus in Refractory Testicular Germ Cell Cancer. Completed NCT01466231 Phase 2 Everolimus
26 A Phase II Study of Sunitinib in Patients With Refractory or Relapsed Germ Cell Tumors Completed NCT00453310 Phase 2 sunitinib malate
27 Randomized Phase II Trial of Intensive Induction Chemotherapy (CBOP/BEP) and Standard BEP Chemotherapy in Poor Prognosis Male Germ Cell Tumors Completed NCT00301782 Phase 2 carboplatin;cisplatin;etoposide phosphate;vincristine sulfate
28 A Phase II Study of Oxaliplatin in Children With Recurrent Solid Tumors Completed NCT00091182 Phase 2 oxaliplatin
29 Phase II Trial of Temozolomide in Patients With Cisplatin-Refractory Germ Cell Tumors Completed NCT00006043 Phase 2 temozolomide
30 Treatment of Recurrent or Resistant Pediatric Malignant Germ Cell Tumors With Paclitaxel, Ifosfamide and Carboplatin Completed NCT00467051 Phase 2 Carboplatin;Ifosfamide;Paclitaxel
31 Accelerated BEP Chemotherapy for Intermediate and High Risk Metastatic Germ Cell Tumor Completed NCT00453232 Phase 2 cisplatin;etoposide
32 A Phase II Study of F-Fluorodeoxyglucose (FluGlucoScan) in Patients With Known or Suspected Cancers of Low Incidence Completed NCT00123773 Phase 2
33 A Study of Paclitaxel, Cisplatin and Ifosfamide as Induction Therapy in the Treatment of Patients Relapsing After BEP Chemotherapy for Metastatic Germ Cell Tumors Completed NCT00004077 Phase 2 cisplatin;ifosfamide;paclitaxel
34 Phase II Study of Paclitaxel Plus Gemcitabine in Refractory Germ Cell Tumors Completed NCT00003518 Phase 2 gemcitabine hydrochloride;paclitaxel
35 Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer Completed NCT01037790 Phase 2 PD-0332991
36 Prevention of DMSO-Related Nausea and Vomiting by Prophylactic Administration of Ondansetron for Patients Receiving Autologous Cryopreserved Peripheral Blood Stem Cells Completed NCT00795769 Phase 2 ondansetron
37 A Non-randomized Phase 2 Study of Alvocidib (Flavopiridol) Plus Oxaliplatin With or Without 5-FU and Leucovorin for Relapsed or Refractory Germ-Cell Tumors Completed NCT00957905 Phase 2 Alvocidib Hydrochloride;Fluorouracil;Leucovorin Calcium;Oxaliplatin
38 Phase 2 Study Cabazitaxel as Salvage Treatment for Cisplatin-resistant Germ Cell Recruiting NCT02478502 Phase 2 cabazitaxel
39 A Biobehavioral Intervention for Young Men With Testicular Cancer: A Pilot Study Recruiting NCT04150848 Phase 2
40 Short-term Testosterone Replacement in Testicular Cancer Survivors to Treat Overweight and Improve Cardiometabolic Risk: A Pilot Study Recruiting NCT03339635 Phase 2 Androgel (Testosterone gel);Placebo gel
41 Multimodality Therapy With Induction Carboplatin/Nab-Paclitaxel/Durvalumab Followed by Surgical Resection and Risk-adapted Adjuvant Therapy for the Treatment of Locally-Advanced and Surgically Resectable Squamous Cell Carcinoma of the Head and Neck Recruiting NCT03174275 Phase 2 Durvalumab;Carboplatin;Nab-paclitaxel;Cisplatin
42 A Phase 1/2 Study of In Situ Vaccination With Tremelimumab and IV Durvalumab (MEDI4736) Plus the Toll-like Receptor Agonist PolyICLC in Subjects With Advanced, Measurable, Biopsy-accessible Cancers Recruiting NCT02643303 Phase 1, Phase 2 Durvalumab;Tremelimumab;Poly ICLC
43 Reduced-dose Radiotherapy Following High-dose Chemotherapy and Autologous Stem Cell Transplantation in Patients With Central Nervous System Non-germinomatous Germ Cell Tumors Recruiting NCT02784054 Phase 2 Carboplatin;Etoposide;Cyclophosphamide;Bleomycin;Thiotepa;Melphalan
44 Reduced Intensity Radio-chemotherapy for Stage IIA/B Seminoma. A Multicenter, Open Label Phase II Trial With Two Cohorts Recruiting NCT03937843 Phase 2 Carboplatin;Cisplatin;Etoposide
45 Phase II Study of Gemcitabine, Carboplatin and VELIPARIB (ABT-888) in Refractory Testicular Germ Cell Cancer Active, not recruiting NCT02860819 Phase 2 Veliparib;Gemcitabine;Carboplatin
46 Phase II Study of Effectiveness of Using Low-dose CT in Patient Undergoing Surveillance for Clinical Stage I Testicular Cancer Active, not recruiting NCT03142802 Phase 2
47 High-dose Chemotherapy for Poor-Prognosis Relapsed Germ-Cell Tumors Active, not recruiting NCT00936936 Phase 2 Gemcitabine;Docetaxel;Melphalan;Carboplatin;Mesna;Ifosfamide;Etoposide
48 Phase II Trial of Paclitaxel, Gemcitabine and Cisplatin in Patients With Relapsing Germ Cell Cancer Terminated NCT00531687 Phase 2 Paclitaxel;Cisplatin;Gemcitabine
49 Multicenter Single Arm Phase II Study of Single Agent Palifosfamide in Recurrent and Incurable Germ Cell Tumors Terminated NCT01808534 Phase 2 palifosfamide
50 A Phase II Study Of Imatinib Mesylate (Gleevec, Formerly Known As STI571; IND 61,135, NSC #716051) In Patients With Refractory Seminoma Terminated NCT00042952 Phase 2 imatinib mesylate

Search NIH Clinical Center for Testicular Cancer

Inferred drug relations via UMLS 71 / NDF-RT 51 :


Chlorambucil
Cisplatin
CISPLATIN PWDR
Cyclophosphamide
Etoposide
etoposide phosphate
Ifosfamide
Methotrexate
Methotrexate Sodium
Vinblastine
Vinblastine Sulfate

Cochrane evidence based reviews: testicular neoplasms

Sources

Genetic Tests for Testicular Cancer

About this section
Sources

Anatomical Context for Testicular Cancer

About this section

The Foundational Model of Anatomy Ontology organs/tissues related to Testicular Cancer:

19
Testicles

MalaCards organs/tissues related to Testicular Cancer:

40
Testis, Lymph Node, Testes, Prostate, Bone Marrow, Bone, Kidney
Sources

Publications for Testicular Cancer

About this section

Articles related to Testicular Cancer:

(show top 50) (show all 6394)
# Title Authors PMID Year
1
Mutations and impaired function of LKB1 in familial and non-familial Peutz-Jeghers syndrome and a sporadic testicular cancer. 61 54 6
9887330 1999
2
Somatic mutations in LKB1 are rare in sporadic colorectal and testicular tumors. 54 61 6
9605748 1998
3
Review: Evolution of evidence on PFOA and health following the assessments of the C8 Science Panel. 61 42
32950793 2020
4
Practices recommendations in the applications of immunohistochemistry and molecular genetics in testicular tumors. Review article. 42 61
33076667 2020
5
Point mutations and deletions of the Bcl10 gene in solid tumors and malignant lymphomas. 6
10582682 1999
6
46, XX Ovotesticular disorder of sex development (true hermaphroditism) with seminoma: A case report. 42
33019456 2020
7
Seminal expression of NY-ESO-1 and MAGE-A4 as markers for the testicular cancer. 54 61
19207618 2009
8
Semen quality in men with disseminated testicular cancer: relation with human chorionic gonadotropin beta-subunit and pituitary gonadal hormones. 61 54
18440530 2009
9
[Place of serum HCG assay in the follow-up of non-HCG-secreting testicular seminomas]. 61 54
18971108 2008
10
Free beta-subunit of human chorionic gonadotropin in serum is a diagnostically sensitive marker of seminomatous testicular cancer. 54 61
18787014 2008
11
False tumor marker surge evoked by peripheral blood stem cell transplantation. 54 61
18515737 2008
12
Late relapse of testicular cancer 21 years after first complete remission: a case report. 61 54
18260359 2008
13
DNMT1 and HDAC1 gene expression in impaired spermatogenesis and testicular cancer. 54 61
16960727 2007
14
[Significance of thcg assay in the management of testicular cancer--the possibility of a standard assay in testicular cancer as an alternative to FbetahCG assay]. 61 54
17302291 2007
15
Immunostaining for placental alkaline phosphatase on fine-needle aspiration specimens to detect noninvasive testicular cancer: a prospective evaluation in cryptorchid men. 54 61
17227503 2007
16
Insulin-like factor 3 gene mutations in testicular dysgenesis syndrome: clinical and functional characterization. 54 61
16687567 2006
17
Y chromosome instability in testicular cancer. 54 61
16483836 2006
18
Immunostaining for placental alkaline phosphatase on fine-needle aspiration specimens to detect noninvasive testicular cancer: a prospective evaluation in cryptorchid men. 61 54
16643476 2006
19
Polymorphisms in RAI and in genes of nucleotide and base excision repair are not associated with risk of testicular cancer. 54 61
15885892 2005
20
[Two cases of testicular cancer with low human chorionic gonadotropin (hCG) levels after treatment]. 61 54
16119815 2005
21
Human tissue kallikrein gene family: applications in cancer. 54 61
15911097 2005
22
Hypermethylation of the 5' CpG island of the gene encoding the serine protease Testisin promotes its loss in testicular tumorigenesis. 61 54
15685234 2005
23
Ethnic variation in the prevalence of AZF deletions in testicular cancer. 61 54
15450403 2004
24
Selecting an appropriate hCG test for managing gestational trophoblastic disease and cancer. 54 61
15305826 2004
25
[Significance of current bio- and molecular-markers in urological cancers]. 54 61
15272577 2004
26
Clinical parameters that predict histology of postchemotherapy retroperitoneal lymph node mass in testicular cancer. 61 54
15242364 2004
27
XIST unmethylated DNA fragments in male-derived plasma as a tumour marker for testicular cancer. 61 54
14723995 2004
28
Stability of the Peutz-Jeghers syndrome kinase LKB1 requires its binding to the molecular chaperones Hsp90/Cdc37. 54 61
14668798 2003
29
[Paraneoplastic hyperthyroidism in a patient with metastasizing teratocarcinoma and excessively high HCG]. 54 61
14579189 2003
30
E- and A-type cyclins as markers for cancer diagnosis and prognosis. 61 54
14510182 2003
31
No AZF deletion in 160 patients with testicular germ cell neoplasia. 61 54
12900510 2003
32
[Endocrine profiles and gonadotropin response to Gn-RH of men with testicular cancer]. 54 61
12910930 2003
33
Frequent promoter hypermethylation of the O6-Methylguanine-DNA Methyltransferase (MGMT) gene in testicular cancer. 61 54
12483540 2002
34
alpha-Catenin expression pattern and DNA image-analysis cytometry have no additional value over primary histology in clinical stage I nonseminomatous testicular cancer. 61 54
11856111 2002
35
[Lung resistance protein analysis in testicular cancer]. 61 54
12563357 2002
36
[A prospect of molecular biology in the field of urologic oncology: mechanisms of carcinogenesis or tumor development in testicular cancer]. 61 54
11771175 2001
37
PET and PLAP in suspected testicular cancer relapse: beware sarcoidosis. 54 61
11762823 2001
38
Organization and chromosomal localization of the murine Testisin gene encoding a serine protease temporally expressed during spermatogenesis. 54 61
11231276 2001
39
Localization, expression and genomic structure of the gene encoding the human serine protease testisin. 61 54
11004480 2000
40
Validation of 125I-hCG as a marker for elimination of hCG and stability of 125I-hCG after in vivo injection in humans. 61 54
10408403 1999
41
125I-labelled human chorionic gonadotrophin (hCG) as an elimination marker in the evaluation of hCG decline during chemotherapy in patients with testicular cancer. 61 54
10408402 1999
42
Semen quality and reproductive hormones before orchiectomy in men with testicular cancer. 61 54
10071288 1999
43
Gonadotrophin secretion patterns in testicular cancer patients with greatly increased human chorionic gonadotrophin serum concentrations. 54 61
9834462 1998
44
Purification and characterization of alkaline phosphatase from human seminomas. 54 61
10359511 1998
45
Tumor markers in hydrocele fluids of patients with benign and malignant scrotal diseases. 54 61
9258097 1997
46
Broad distribution of the multidrug resistance-related vault lung resistance protein in normal human tissues and tumors. 61 54
8774142 1996
47
Immunological recognition and clinical significance of nicked human chorionic gonadotropin in testicular cancer. 54 61
7527309 1994
48
Human chorionic gonadotropin (hCG) and its free subunits in hydrocele fluids and neoplastic tissue of testicular cancer patients: insights into the in vivo hCG-secretion pattern. 61 54
7923124 1994
49
Role of human chorionic gonadotropin in patients with pure seminoma. 61 54
7525293 1994
50
[Establishment and characterization of a new human testicular germ cell tumor cell line (TCam-2)]. 54 61
8394948 1993
Sources

Variations for Testicular Cancer

About this section

ClinVar genetic disease variations for Testicular Cancer:

6 (show all 30)
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 STK11 NM_000455.4(STK11):c.488G>A (p.Gly163Asp) SNV Pathogenic 7448 rs137853078 19:1220395-1220395 19:1220396-1220396
2 FGFR3 NM_001163213.1(FGFR3):c.746C>G (p.Ser249Cys) SNV Pathogenic 16339 rs121913483 4:1803568-1803568 4:1801841-1801841
3 FGFR3 NM_000142.5(FGFR3):c.1949A>C (p.Lys650Thr) SNV Pathogenic 65855 rs121913105 4:1807890-1807890 4:1806163-1806163
4 BCL10 NM_003921.5(BCL10):c.488C>T (p.Thr163Met) SNV Pathogenic 30361 rs370432633 1:85733524-85733524 1:85267841-85267841
5 FGFR3 NM_000142.5(FGFR3):c.742C>T (p.Arg248Cys) SNV Pathogenic 16332 rs121913482 4:1803564-1803564 4:1801837-1801837
6 FGFR3 NM_000142.5(FGFR3):c.749C>G (p.Pro250Arg) SNV Pathogenic 16340 rs4647924 4:1803571-1803571 4:1801844-1801844
7 FGFR3 NM_000142.5(FGFR3):c.1138G>A SNV Pathogenic 16327 rs28931614 4:1806119-1806119 4:1804392-1804392
8 FGFR3 NM_000142.5(FGFR3):c.1620C>G (p.Asn540Lys) SNV Pathogenic 16338 rs28933068 4:1807371-1807371 4:1805644-1805644
9 STK11 NM_000455.4(STK11):c.719C>G (p.Ser240Trp) SNV Likely pathogenic 182902 rs730881976 19:1220701-1220701 19:1220702-1220702
10 KIT NM_000222.2(KIT):c.200C>G (p.Thr67Ser) SNV Uncertain significance 237252 rs144933028 4:55561810-55561810 4:54695644-54695644
11 KIT NM_000222.2(KIT):c.302A>G (p.His101Arg) SNV Uncertain significance 458940 rs1274601103 4:55561912-55561912 4:54695746-54695746
12 KIT NM_000222.2(KIT):c.1553C>T (p.Pro518Leu) SNV Uncertain significance 237245 rs569408054 4:55593396-55593396 4:54727230-54727230
13 KIT NM_000222.2(KIT):c.2057G>A (p.Arg686His) SNV Uncertain significance 458902 rs143772138 4:55595567-55595567 4:54729401-54729401
14 KIT NM_000222.2(KIT):c.2104C>G (p.Leu702Val) SNV Uncertain significance 409779 rs768847037 4:55595614-55595614 4:54729448-54729448
15 KIT NM_000222.2(KIT):c.2294A>G (p.Asp765Gly) SNV Uncertain significance 409730 rs1060502545 4:55598097-55598097 4:54731931-54731931
16 KIT NM_000222.2(KIT):c.2836C>T (p.Arg946Ter) SNV Uncertain significance 576610 rs139000082 4:55604628-55604628 4:54738462-54738462
17 KIT NM_000222.2(KIT):c.2863G>T (p.Val955Leu) SNV Uncertain significance 409783 rs1060502568 4:55604655-55604655 4:54738489-54738489
18 KIT NM_000222.2(KIT):c.2881G>A (p.Gly961Ser) SNV Uncertain significance 237271 rs773828910 4:55604673-55604673 4:54738507-54738507
19 KIT NM_000222.2(KIT):c.2887A>G (p.Thr963Ala) SNV Uncertain significance 409774 rs773709702 4:55604679-55604679 4:54738513-54738513
20 KIT NM_000222.2(KIT):c.2900C>G (p.Ser967Cys) SNV Uncertain significance 458936 rs1232060384 4:55604692-55604692 4:54738526-54738526
21 STK11 NM_000455.4(STK11):c.566C>T (p.Thr189Ile) SNV Uncertain significance 141128 rs587781515 19:1220473-1220473 19:1220474-1220474
22 STK11 NM_000455.4(STK11):c.632G>A (p.Arg211Gln) SNV Uncertain significance 182910 rs730881982 19:1220614-1220614 19:1220615-1220615
23 STK11 NM_000455.4(STK11):c.1012G>A (p.Val338Met) SNV Uncertain significance 142198 rs587782302 19:1223075-1223075 19:1223076-1223076
24 STK11 NM_000455.4(STK11):c.1195C>A (p.Gln399Lys) SNV Uncertain significance 403791 rs1060499968 19:1226539-1226539 19:1226540-1226540
25 STK11 NM_000455.4(STK11):c.1243C>G (p.Arg415Gly) SNV Uncertain significance 220264 rs864622448 19:1226587-1226587 19:1226588-1226588
26 FGFR3 NM_000142.5(FGFR3):c.200G>A (p.Gly67Asp) SNV Uncertain significance 546226 rs369232922 4:1801071-1801071 4:1799344-1799344
27 FGFR3 NM_000142.5(FGFR3):c.1993G>T (p.Ala665Ser) SNV Uncertain significance 465350 rs764892330 4:1808017-1808017 4:1806290-1806290
28 FGFR3 NM_000142.5(FGFR3):c.2153A>G (p.Asn718Ser) SNV Uncertain significance 521225 rs139773438 4:1808395-1808395 4:1806668-1806668
29 KIT NM_000222.2(KIT):c.101C>T (p.Pro34Leu) SNV Uncertain significance 409788 rs55755457 4:55561711-55561711 4:54695545-54695545
30 STK11 NM_000455.4(STK11):c.464+5G>A SNV Uncertain significance 141354 rs587781681 19:1219417-1219417 19:1219418-1219418

Copy number variations for Testicular Cancer from CNVD:

7
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 61546 12 1 35400000 Gain Testicular cancer
2 202070 5 76900000 102800000 Loss Testicular cancer
3 217038 7 1 158821424 Gain Testicular cancer
4 237464 8 23300000 146274826 Gain Testicular cancer
5 262544 X 37500000 154913754 Gain Testicular cancer
6 262545 X 37500000 154913754 Gain Testicular cancer
7 266960 Y 174481503 174538309 Deletion AZF1 Testicular cancer
Sources

Expression for Testicular Cancer

About this section
Search GEO for disease gene expression data for Testicular Cancer.
Sources

Pathways for Testicular Cancer

About this section
Sources

GO Terms for Testicular Cancer

About this section

Biological processes related to Testicular Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 apoptotic process GO:0006915 9.72 STK11 FGFR3 CGB5 CGB3 BCL10
2 female gamete generation GO:0007292 9.26 CGB5 CGB3
3 cell-cell signaling GO:0007267 9.26 INSL3 FGFR3 CGB5 CGB3
4 peptide hormone processing GO:0016486 9.16 CGB5 CGB3
5 hormone-mediated signaling pathway GO:0009755 8.8 RXFP2 CGB5 CGB3

Molecular functions related to Testicular Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 hormone activity GO:0005179 8.8 INSL3 CGB5 CGB3
Sources

Sources for Testicular Cancer

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....